证券代码：600518 证券简称：康美药业 编号：临2025-032 康美药业股份有限公司 关于收到补偿款的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 获得补偿款金额：461.32 万元。 公司于近日收到出租方支付的补偿款合计 461.32 万元，占公司最近一个会 计年度经审计净利润的比例为 38.18%。 二、补偿的类型及其对上市公司的影响 根据《企业会计准则》等相关规定，公司上述获得的补偿款将一次性计入当 期损益，预计对 2025 年度利润将产生一定的积极影响。 上述补偿具体的会计处理以及最终对公司 2025 年度损益的影响以年度审计 机构确认的结果为准。敬请广大投资者注意投资风险。 特此公告。 康美药业股份有限公司董事会 二〇二五年十月一日 1 对当期损益的影响：上述补偿款将一次性计入当期损益，最终对公司 2025 年度损益的影响以年度审计机构确认的结果为准。 一、获得补偿款的基本情况 康美药业股份有限公司（以下简称公司）由于日常经营需要，与深圳市新安 实业有限公司（以下简称出租方）签订房屋租赁 ...

Core Viewpoint - The China Securities Regulatory Commission (CSRC) is intensifying its regulatory enforcement against financial fraud and information disclosure violations, aiming to enhance market integrity and investor confidence [1][2][3]. Regulatory Framework - Recent legal reforms, including the new Securities Law and related regulations, have established a robust regulatory framework for capital markets, providing a solid basis for enforcement actions [2][3]. - The CSRC has issued over 2,200 administrative penalties for financial fraud and market manipulation during the 14th Five-Year Plan period, with fines totaling 41.4 billion yuan, marking increases of 58% and 30% respectively compared to the previous five-year period [2][3]. Enforcement Actions - The CSRC is focusing on severe violations such as financial fraud and insider trading, with notable cases leading to significant penalties, including a 2.25 billion yuan fine against Zhongke Huayuan Titanium Co., Ltd. for compliance violations [3][4]. - Since last year, the CSRC has investigated 67 delisted companies for illegal activities, with 33 cases referred for potential criminal prosecution [3][4]. Investor Protection - The regulatory bodies are enhancing investor protection mechanisms, including the introduction of new judicial interpretations and multi-faceted dispute resolution frameworks to support investor rights [5][6]. - Landmark cases, such as the special representative litigation against Kangmei Pharmaceutical, have resulted in substantial compensation for investors, demonstrating the effectiveness of the new protective measures [5][6]. Comprehensive Accountability - The CSRC is promoting a multi-layered accountability system that integrates administrative, civil, and criminal responsibilities to strengthen deterrence against securities violations [8][9]. - Over the past five years, the CSRC has referred more than 700 cases to law enforcement, leading to serious criminal accountability for numerous offenders [9]. Future Directions - Experts suggest that future regulatory efforts should focus on precise enforcement against financial fraud while ensuring that intermediary institutions fulfill their responsibilities as gatekeepers [4][6]. - There is a call for a "one-stop" platform for investor rights protection, integrating various forms of dispute resolution to facilitate easier access for small investors [7].

Group 1 - The core viewpoint emphasizes the importance of building a "safe, standardized, transparent, open, vibrant, and resilient" capital market, highlighting risk prevention and strong regulation as priorities [1] - The regulatory body is committed to maintaining market stability through comprehensive monitoring and early warning systems, as well as enhancing cross-market risk prevention mechanisms [1] - The bond default rate in the exchange market remains low at around 1%, indicating effective risk control measures [1] Group 2 - Regulatory enforcement has been significantly strengthened, focusing on financial fraud and establishing a comprehensive deterrent system against such violations [2] - Major penalties have been imposed for financial misconduct, including a record fine of 4.175 billion yuan against Evergrande and 325 million yuan against its auditing firm [2] - Over 700 cases have been referred to law enforcement for criminal accountability in the past five years, reflecting a rigorous approach to legal enforcement [2] Group 3 - Investor protection measures have been enhanced, with new regulations on share reduction, quantitative trading, and short selling being implemented [3] - Landmark cases have resulted in substantial compensation for investors, including approximately 2.46 billion yuan for the Kangmei Pharmaceutical case and 1.09 billion yuan for the Zijing Storage case [3] - A comprehensive investor protection system is being developed, ensuring accountability and quality evaluation for intermediary institutions [3]

从资金流向上来看，当日中药板块主力资金净流出10.76亿元，游资资金净流入2.72亿元，散户资金净流 入8.04亿元。中药板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入(元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 300878 维康药业 | | 3055.24万 | 13.01% | 808.07万 | 3.44% | -3863.30万 | -16.45% | | 600572 | 康恩贝 | 1028.82万 | 7.44% | 336.93万 | 2.44% | -1365.75万 | -9.87% | | 000423 | 东阿阿胶 | 766.16万 | 2.06% | -1729.21万 | -4.64% | 963.05万 | 2.59% | | 300391 | *ST长药 | 358.88万 | 7.94% | -212.58万 | -4.70% | -146.30万 | -3.24% | | 002412 汉森制药 ...

Market Overview - The Chinese medicine sector experienced a decline of 0.37% on September 15, with ST Xiangxue leading the drop [1] - The Shanghai Composite Index closed at 3860.5, down 0.26%, while the Shenzhen Component Index rose by 0.63% to 13005.77 [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - Wanbangde (002082) with a closing price of 11.33, up 10.00% [1] - Kangmei Pharmaceutical (600518) at 2.18, up 4.81% [1] - Zhongheng Group (600252) at 2.88, up 3.97% [1] - Conversely, ST Xiangxue (300147) saw a significant decline of 4.39%, closing at 10.66 [2] - Other notable decliners included: - Enwei Pharmaceutical (301331) down 3.25% [2] - Zhendong Pharmaceutical (300158) down 2.97% [2] Trading Volume and Capital Flow - The Chinese medicine sector recorded a net outflow of 470 million yuan from institutional investors, while retail investors saw a net inflow of 398 million yuan [2] - The trading volume for major stocks included: - Kangmei Pharmaceutical with a trading volume of 9.5463 million shares and a transaction value of 2.086 billion yuan [1] - Wanbangde with a trading volume of 414,700 shares and a transaction value of 448 million yuan [1] Capital Inflow Analysis - Major stocks with significant net inflows from institutional investors included: - Kangmei Pharmaceutical with a net inflow of 18.7 million yuan [3] - Wanbangde with a net inflow of 67.5 million yuan [3] - Conversely, stocks like Zhongheng Group and Panzhong Pharmaceutical experienced net outflows from institutional investors [3]

Market Overview - On September 12, the Chinese medicine sector declined by 0.56%, with Qianjin Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3883.69, up 0.22%, while the Shenzhen Component Index closed at 12996.38, up 0.13% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - Wanbangde (002082) with a closing price of 10.25, up 3.64% on a trading volume of 228,400 shares and a turnover of 230 million yuan [1] - Jiuzhitang (000989) closed at 10.91, up 2.83% with a trading volume of 212,800 shares and a turnover of 233 million yuan [1] - Kangmei Pharmaceutical (600518) closed at 2.07, up 2.48% with a trading volume of 4,321,600 shares and a turnover of 891 million yuan [1] - Conversely, significant decliners included: - Qianjin Pharmaceutical (600479) closed at 11.05, down 1.60% with a trading volume of 115,400 shares and a turnover of 128 million yuan [2] - Jianmin Group (600976) closed at 42.45, down 1.12% with a trading volume of 18,100 shares and a turnover of 77 million yuan [2] - Hansen Pharmaceutical (002412) closed at 6.74, down 1.03% with a trading volume of 133,300 shares and a turnover of 89 million yuan [2] Capital Flow - The Chinese medicine sector experienced a net outflow of 642 million yuan from institutional investors, while retail investors saw a net inflow of 448 million yuan [2] - The following stocks had notable capital flows: - Kangmei Pharmaceutical had a net inflow of 65.97 million yuan from institutional investors, but a net outflow of 14.99 million yuan from retail investors [3] - Jiuzhitang saw a net inflow of 33.21 million yuan from institutional investors, with a net outflow of 16.66 million yuan from retail investors [3] - Wanbangde had a net inflow of 30.43 million yuan from institutional investors, but also faced a net outflow of 19.37 million yuan from retail investors [3]

Market Overview - The Chinese medicine sector rose by 0.75% on September 1, with Zhendong Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3875.53, up 0.46%, while the Shenzhen Component Index closed at 12828.95, up 1.05% [1] Top Gainers in Chinese Medicine Sector - Zhendong Pharmaceutical (300158) closed at 9.21, up 6.11% with a trading volume of 1.2136 million shares and a turnover of 1.101 billion yuan [1] - Qidi Pharmaceutical (000590) closed at 12.33, up 4.14% with a trading volume of 140,800 shares and a turnover of 174 million yuan [1] - Kangmei Pharmaceutical (600518) closed at 2.12, up 3.92% with a trading volume of 5.5195 million shares and a turnover of 1.165 billion yuan [1] Top Losers in Chinese Medicine Sector - Tianmu Pharmaceutical (600671) closed at 19.44, down 1.87% with a trading volume of 86,000 shares and a turnover of 170 million yuan [2] - Jilin Aodong (000623) closed at 20.13, down 1.66% with a trading volume of 284,000 shares and a turnover of 573 million yuan [2] - *ST Changyao (300391) closed at 4.19, down 1.64% with a trading volume of 86,000 shares and a turnover of 36.1 million yuan [2] Capital Flow Analysis - The Chinese medicine sector experienced a net outflow of 29.7085 million yuan from institutional investors, while retail investors saw a net inflow of 253 million yuan [2][3] - Notable net inflows from retail investors were observed in Yunnan Baiyao (000538) with 436.788 million yuan and in Zhongsheng Pharmaceutical (002317) with 82.0845 million yuan [3] Individual Stock Capital Flow - Yunnan Baiyao (000538) had a net inflow of 188 million yuan from institutional investors, but a net outflow of 144 million yuan from speculative funds [3] - Zhongsheng Pharmaceutical (002317) saw a net inflow of 54.7945 million yuan from institutional investors, while retail investors experienced a net outflow of 82.0845 million yuan [3] - Dong'e Ejiao (000423) had a net inflow of 53.6307 million yuan from institutional investors, with a net outflow of 40.1030 million yuan from speculative funds [3]

Market Overview - As of 10:29 AM today, the Shanghai Composite Index stands at 3864.71 points, above the annual line, with a change of 0.18% [1] - The total trading volume of A-shares today is 138.21 billion yuan [1] Stocks Breaking Annual Line - A total of 41 A-shares have surpassed the annual line today, with notable stocks showing significant deviation rates [1] - The stocks with the highest deviation rates include: - Energy Iron Han (节能铁汉) with a deviation rate of 14.24% and a daily increase of 14.69% [1] - Qidi Environment (启迪环境) with a deviation rate of 7.10% and a daily increase of 10.26% [1] - ST Quanwei (ST泉为) with a deviation rate of 6.60% and a daily increase of 9.06% [1] Detailed Stock Performance - The following table summarizes the performance of selected stocks that have recently broken the annual line: | Stock Code | Stock Name | Daily Change (%) | Turnover Rate (%) | Annual Line (yuan) | Latest Price (yuan) | Deviation Rate (%) | | --- | --- | --- | --- | --- | --- | --- | | 300197 | 节能铁汉 | 14.69 | 5.66 | 2.12 | 2.42 | 14.24 | | 000826 | 启迪环境 | 10.26 | 8.19 | 2.01 | 2.15 | 7.10 | | 300716 | ST泉为 | 9.06 | 3.95 | 10.05 | 10.71 | 6.60 | | 001215 | 千味央厨 | 3.57 | 2.39 | 29.19 | 30.19 | 3.43 | | 601882 | 海天精工 | 5.10 | 1.67 | 20.52 | 21.02 | 2.45 | | 601298 | 青岛港 | 2.59 | 0.45 | 8.54 | 8.72 | 2.09 | | 002771 | 真视通 | 3.22 | 3.18 | 17.64 | 17.97 | 1.85 | | 600653 | 申华控股 | 2.56 | 1.44 | 1.97 | 2.00 | 1.76 | | 300141 | 和顺电气 | 1.77 | 1.04 | 9.07 | 9.22 | 1.63 | | 002390 | 信邦制药 | 2.75 | 1.17 | 3.68 | 3.73 | 1.46 | | 600189 | 泉阳泉 | 1.49 | 1.23 | 7.38 | 7.48 | 1.41 | | 601328 | 交通银行 | 1.51 | 0.53 | 7.28 | 7.38 | 1.40 | | 600518 | 康美药业 | 4.41 | 2.72 | 2.10 | 2.13 | 1.25 | | 300318 | 博晖创新 | 1.18 | 0.45 | 5.92 | 5.98 | 1.08 | | 300144 | 宋城演艺 | 1.49 | 1.35 | 8.82 | 8.88 | 0.72 | | 600916 | 中国黄金 | 1.83 | 2.15 | 8.27 | 8.33 | 0.71 | | 300067 | 安诺其 | 1.48 | 1.87 | 5.44 | 5.47 | 0.61 | | 600272 | 开开实业 | 1.36 | 1.09 | 13.39 | 13.45 | 0.48 | | 603310 | 巍华新材 | 0.61 | 0.69 | 17.96 | 18.05 | 0.47 | | 603718 | 海利生物 | 0.70 | 0.66 | 7.17 | 7.20 | 0.41 | | 603768 | 常青股份 | 0.95 | 0.80 | 12.72 | 12.76 | 0.35 | | 600062 | 华润双鹤 | 1.08 | 0.71 | 19.60 | 19.66 | 0.30 | | 300784 | 利安科技 | 2.40 | 3.84 | 56.62 | 56.78 | 0.29 | | 600236 | 桂冠电力 | 0.32 | 0.05 | 6.32 | 6.34 | 0.28 | | 300076 | GQY视讯 | 1.71 | 1.47 | 6.54 | 6.56 | 0.25 | | 601898 | 中煤能源 | 0.97 | 0.11 | 11.42 | 11.45 | 0.24 | [1]

Core Viewpoint - Kangmei Pharmaceutical (600518) reported a year-on-year increase in both revenue and net profit for the first half of 2025, indicating positive financial performance despite challenges in the industry [1]. Financial Performance - Total revenue for the first half of 2025 reached 2.577 billion yuan, a 4.17% increase compared to 2.474 billion yuan in the same period of 2024 [1]. - Net profit attributable to shareholders was 16.9014 million yuan, up 7.24% from 15.7603 million yuan in the previous year [1]. - In Q2 2025, total revenue was 1.278 billion yuan, reflecting a 0.39% increase year-on-year, while net profit for the quarter was 8.3956 million yuan, a 1.29% increase [1]. Profitability Metrics - Gross margin improved to 18.84%, a significant increase of 29.4% year-on-year [1]. - Net margin slightly decreased to 0.71%, down 2.96% from the previous year [1]. - Total expenses (selling, administrative, and financial) amounted to 480 million yuan, accounting for 18.61% of revenue, which is a 5.75% increase year-on-year [1]. Balance Sheet Highlights - Cash and cash equivalents increased to 903 million yuan, a 13.54% rise from 795 million yuan [1]. - Accounts receivable rose to 2.557 billion yuan, up 17.59% from 2.174 billion yuan [1]. - Interest-bearing debt significantly decreased to 47.393 million yuan, a reduction of 94.52% from 865 million yuan [1]. Cash Flow and Earnings - Earnings per share remained at 0.00 yuan, indicating no change [1]. - Operating cash flow per share improved to -0.01 yuan, a 74.25% increase from -0.02 yuan [1]. Business Evaluation - The company's return on invested capital (ROIC) was 0.22% last year, indicating weak capital returns [3]. - Historical data shows a median ROIC of 2.93% over the past decade, with a significant drop to -76.36% in 2020 [3]. - The business model relies heavily on research and marketing, necessitating a thorough examination of these driving factors [3]. Financial Health Indicators - Cash flow situation is concerning, with cash and cash equivalents to current liabilities at only 27.18% [3]. - Financial expenses have been a consistent issue, with negative net cash flow from operating activities over the past three years [3]. - Accounts receivable have reached an alarming ratio of 29,822.7% relative to profit, indicating potential liquidity issues [3].

康美药业8月29日披露半年报，公司上半年实现营业收入25.77亿元，同比增长4.17%；归属于上市公司 股东的净利润1690.14万元，同比增长7.24%；基本每股收益0.001元/股。 ...